Magenta, Heidelberg Pharma Launch Bone Marrow Transplant ADC Collaboration

Magenta Therapeutics will license Heidelberg Pharma’s Antibody Targeted Amanitin Conjugates (ATAC) platform and combine it with its stem cell platform to develop targeted antibody–drug conjugates (ADCs) for conditioning regimens in bone marrow transplantation, through a collaboration that could generate up to $334 million-plus for Heidelberg, the companies said.Through their exclusive multitarget research agreement, Magenta and Heidelberg said, they plan to develop ADCs with propriet